The pros and cons of traditional Chinese medicines in the treatment of COVID-19.
作者信息
Wang Yali, Zeng Xian, Zhao Yufen, Chen Weiping, Chen Yu Zong
机构信息
The Institute of Drug Discovery Technology, Ningbo University, Ningbo 315211, PR China; Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, 117543, Singapore.
Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai 201203, PR China.
出版信息
Pharmacol Res. 2020 Jul;157:104873. doi: 10.1016/j.phrs.2020.104873. Epub 2020 May 3.
Abstract
摘要
相似文献
1
The pros and cons of traditional Chinese medicines in the treatment of COVID-19.中药治疗新型冠状病毒肺炎的利弊
Pharmacol Res. 2020 Jul;157:104873. doi: 10.1016/j.phrs.2020.104873. Epub 2020 May 3.
2
Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19.促进中药抗COVID-19机制研究的数据库
Pharmacol Res. 2020 Sep;159:104989. doi: 10.1016/j.phrs.2020.104989. Epub 2020 Jun 2.
3
The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.血必净注射液（XBJ）治疗成人新型冠状病毒肺炎重型及危重型的研究及XBJ对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的抑制作用
Pharmacol Res. 2020 Oct;160:105073. doi: 10.1016/j.phrs.2020.105073. Epub 2020 Jul 9.
4
Use of herbal drugs to treat COVID-19 should be with caution.使用草药治疗新冠病毒疾病时应谨慎。
Lancet. 2020 May 30;395(10238):1689-1690. doi: 10.1016/S0140-6736(20)31143-0. Epub 2020 May 15.
5
A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).治疗药物和中草药抗 SARS-CoV-2（COVID-19）的综述。
Pharmacol Res. 2020 Aug;158:104929. doi: 10.1016/j.phrs.2020.104929. Epub 2020 May 20.
6
Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.蒲地蓝消炎口服液（PDL）对新型冠状病毒肺炎的体内外治疗效果
Signal Transduct Target Ther. 2020 May 8;5(1):66. doi: 10.1038/s41392-020-0176-0.
7
East meets West in COVID-19 therapeutics.在新冠病毒治疗中，东西方相遇了。
Pharmacol Res. 2020 Sep;159:105008. doi: 10.1016/j.phrs.2020.105008. Epub 2020 Jun 9.
8
Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).中药治疗 2019 年冠状病毒病（COVID-19）的潜在作用机制研究进展。
Pharmacol Res. 2020 Aug;158:104939. doi: 10.1016/j.phrs.2020.104939. Epub 2020 May 21.
9
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.针对 SARS-CoV-2 感染的候选化学药物和中药的抗病毒机制。
Virus Res. 2020 Sep;286:198073. doi: 10.1016/j.virusres.2020.198073. Epub 2020 Jun 24.
10
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.中国治疗新型冠状病毒肺炎（COVID-19）的潜在药物。
Virus Res. 2020 Sep;286:198057. doi: 10.1016/j.virusres.2020.198057. Epub 2020 Jun 9.
引用本文的文献
1
Challenges in integrating traditional Chinese medicine and gut microbiota research for insomnia treatment.将中医与肠道微生物群研究整合用于失眠治疗面临的挑战。
World J Clin Cases. 2024 Oct 16;12(29):6271-6274. doi: 10.12998/wjcc.v12.i29.6271.
2
NPASS database update 2023: quantitative natural product activity and species source database for biomedical research.NPASS 数据库更新 2023：用于生物医药研究的定量天然产物活性和物种来源数据库。
Nucleic Acids Res. 2023 Jan 6;51(D1):D621-D628. doi: 10.1093/nar/gkac1069.
3
TCM2COVID: A resource of anti-COVID-19 traditional Chinese medicine with effects and mechanisms.中医防治新冠肺炎：一种具有疗效和作用机制的抗新冠病毒中药资源
Imeta. 2022 Aug 5;1(4):e42. doi: 10.1002/imt2.42.
4
Chinese Medicine Meets Conventional Medicine in Targeting COVID-19 Pathophysiology, Complications and Comorbidities.中医与传统医学携手应对新冠病毒的病理生理学、并发症及合并症
Chin J Integr Med. 2022 Jul;28(7):627-635. doi: 10.1007/s11655-022-3573-0. Epub 2022 May 18.
5
The effect of carvacrol on respiratory syncytial virus infection in mice model: caution in the use of herbal medicines.香芹酚对小鼠模型中呼吸道合胞病毒感染的影响：使用草药需谨慎。
Iran J Microbiol. 2021 Oct;13(5):712-717. doi: 10.18502/ijm.v13i5.7438.
6
Adverse Cardiovascular Effects of Anti-COVID-19 Drugs.抗新冠病毒药物的心血管不良影响。
Front Pharmacol. 2021 Aug 25;12:699949. doi: 10.3389/fphar.2021.699949. eCollection 2021.
7
Monocytes and macrophages in COVID-19: Friends and foes.新型冠状病毒肺炎中的单核细胞和巨噬细胞：亦敌亦友。
Life Sci. 2021 Mar 15;269:119010. doi: 10.1016/j.lfs.2020.119010. Epub 2021 Jan 14.
8
Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.理解新冠疫情：分子机制与潜在治疗策略。一项基于证据的综述。
J Inflamm Res. 2021 Jan 7;14:13-56. doi: 10.2147/JIR.S282213. eCollection 2021.
9
The database-based strategy may overstate the potential effects of traditional Chinese medicine against COVID-19.基于数据库的策略可能高估了中药对新冠病毒的潜在作用。
Pharmacol Res. 2020 Sep;159:105046. doi: 10.1016/j.phrs.2020.105046. Epub 2020 Jun 23.
10
East meets West in COVID-19 therapeutics.在新冠病毒治疗中，东西方相遇了。
Pharmacol Res. 2020 Sep;159:105008. doi: 10.1016/j.phrs.2020.105008. Epub 2020 Jun 9.
本文引用的文献
1
The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good.使用中药治疗新型冠状病毒可能弊大于利。
Pharmacol Res. 2020 Jun;156:104776. doi: 10.1016/j.phrs.2020.104776. Epub 2020 Apr 3.
2
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).连花清瘟对新型冠状病毒（SARS-CoV-2）具有抗病毒和抗炎作用。
Pharmacol Res. 2020 Jun;156:104761. doi: 10.1016/j.phrs.2020.104761. Epub 2020 Mar 20.
3
Traditional Chinese medicine for COVID-19 treatment.用于治疗新冠肺炎的中药。
Pharmacol Res. 2020 May;155:104743. doi: 10.1016/j.phrs.2020.104743. Epub 2020 Mar 4.
4
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).新型冠状病毒（2019-nCoV）感染的肺炎快速诊治指南（标准版）。
Mil Med Res. 2020 Feb 6;7(1):4. doi: 10.1186/s40779-020-0233-6.
5
Integrative omics for health and disease.整体医学组学与健康和疾病。
Nat Rev Genet. 2018 May;19(5):299-310. doi: 10.1038/nrg.2018.4. Epub 2018 Feb 26.
6
The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function.中药方剂连花清瘟胶囊通过抑制病毒增殖发挥抗流感活性，并影响免疫功能。
BMC Complement Altern Med. 2017 Feb 24;17(1):130. doi: 10.1186/s12906-017-1585-7.
Zotero 插件